{"id":6326,"date":"2024-10-02T19:11:29","date_gmt":"2024-10-02T19:11:29","guid":{"rendered":"https:\/\/www.roctavian.com\/en-us\/?page_id=6326"},"modified":"2025-12-17T15:57:04","modified_gmt":"2025-12-17T15:57:04","slug":"andrew-s","status":"publish","type":"page","link":"https:\/\/www.roctavian.com\/en-us\/roctavian-stories\/andrew-s\/","title":{"rendered":"ANDREW-S"},"content":{"rendered":"
\n
\n
\n \n
\n

Andrew S. Transcript<\/h1>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
\n
\n
\n \n
\n

[ON SCREEN TEXT]
\nROCTAVIAN logo<\/p>\n

[NARRATOR AND ON SCREEN TEXT]
\nWhat is ROCTAVIAN?<\/p>\n

ROCTAVIAN is a one-time gene therapy used for the treatment of adults with severe hemophilia A who do not have antibodies to the virus, AAV5 which is determined by a blood test. ROCTAVIAN uses a modified virus, called a vector, to deliver a working copy of the Factor VIII gene to liver cells to enable your body to produce clotting factor on its own, which helps the blood to clot and prevents or reduces the occurrence of bleeding. The modified virus does not contain viral DNA and does not cause disease in humans.<\/p>\n

[ON SCREEN TEXT]
\nMY ROCTAVIAN EXPERIENCE
\nMEET ANDREW
\nROCTAVIAN clinical study participant<\/p>\n

[ANDREW S.]
\nMy name is Andrew. I live in Fort Collins, Colorado. I was born with severe hemophilia A.<\/p>\n

My brother\u2019s 20 months older than me and also has severe hemophilia A. It was great to have a partner, have an ally in hemophilia. And he also kind of paved the way for me, showed me, what life would look like as a hemophiliac. Hemophilia affected me in a lot of different ways. It limited some of the activities I could do, but it also made me who I am.<\/p>\n

I am happily married almost 15 years.<\/p>\n

I have three kids, a boy and two little girls. I just cherish them and love being a dad. We spend a lot of time outdoors\u2014biking and playing soccer and just generally exploring.<\/p>\n

Preparing for, infusions or, or for trips caused a decent amount of anxiety for me. I was always aware of where the nearest hospital would be, what my, my factor level was at, how many shots I brought, did I remember needles?<\/p>\n

[ON SCREEN TEXT]
\nAndrew received his ROCTAVIAN infusion in October 2018.<\/p>\n

[ANDREW S.]
\nI first heard about ROCTAVIAN from my brother.<\/p>\n

[ON SCREEN TEXT AND GRAPHIC]
\nCONSIDERING ROCTAVIAN<\/p>\n

[ON SCREEN TEXT AND GRAPHIC]
\nIMPORTANT SAFETY INFORMATION<\/p>\n

Do not take ROCTAVIAN if you have an active infection or if you have a long-term infection that is not controlled by the medicines you take, have scarring of the liver (significant liver fibrosis or cirrhosis), are allergic to mannitol (an inactive ingredient in ROCTAVIAN).<\/p>\n

Please see additional safety information throughout and at the end of this video.<\/p>\n

[ANDREW S.]
\nI was excited, and he was, too, about what this could mean for our lives. And I remember us just daydreaming about what it could lead to in our treatment of hemophilia.<\/p>\n

[ON SCREEN TEXT]
\n5 years after ROCTAVIAN, more than 70% of people who had responded to ROCTAVIAN stopped\u2014and stayed off\u2014continuous prophylaxis<\/p>\n

ROCTAVIAN was studied in 112 people whose data was collected for at least 6 months before their infusion (rollover population) and 22 people who immediately received their infusion (directly enrolled population).<\/p>\n

ROCTAVIAN worked for 71% (80\/112) of people in the rollover population and 59% (13\/22) of people in the directly enrolled population throughout the 5-year follow-up period.<\/p>\n

Prophylaxis is defined as the ongoing use of Factor VIII or another treatment to prevent bleeds.<\/p>\n

The follow-up period began 5 weeks or more after administration and consists of a median follow-up of 5 years with a range of 1.7 to 5.2 years.<\/p>\n

[Infographic 70% of people]<\/p>\n

[ON SCREEN TEXT]
\nSafety profile of ROCTAVIAN after 5 years<\/p>\n

The safety of ROCTAVIAN is being evaluated in a clinical trial<\/p>\n